Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

488 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.
Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Younes A, et al. Among authors: copeland ar. Blood. 2012 May 3;119(18):4123-8. doi: 10.1182/blood-2012-01-405456. Epub 2012 Feb 27. Blood. 2012. PMID: 22371887 Free PMC article. Clinical Trial.
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A, Berdeja JG, Patel MR, Flinn I, Gerecitano JF, Neelapu SS, Kelly KR, Copeland AR, Akins A, Clancy MS, Gong L, Wang J, Ma A, Viner JL, Oki Y. Younes A, et al. Among authors: copeland ar. Lancet Oncol. 2016 May;17(5):622-31. doi: 10.1016/S1470-2045(15)00584-7. Epub 2016 Mar 31. Lancet Oncol. 2016. PMID: 27049457 Free PMC article. Clinical Trial.
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.
Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Hu B, et al. Among authors: copeland ar. Leuk Lymphoma. 2018 Apr;59(4):863-870. doi: 10.1080/10428194.2017.1359741. Epub 2017 Aug 9. Leuk Lymphoma. 2018. PMID: 28792260 Clinical Trial.
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.
Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J, Li Z, Drouin M, Patterson T, Ward MR, Paulus JK, Ji Y, Medeiros LJ, Martell RE. Younes A, et al. Among authors: copeland a. Lancet Oncol. 2011 Dec;12(13):1222-8. doi: 10.1016/S1470-2045(11)70265-0. Epub 2011 Oct 25. Lancet Oncol. 2011. PMID: 22033282 Free PMC article. Clinical Trial.
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, Lambert JM, Morariu-Zamfir R, Payrard S, Gordon LI. Younes A, et al. Among authors: copeland a. J Clin Oncol. 2012 Aug 1;30(22):2776-82. doi: 10.1200/JCO.2011.39.4403. Epub 2012 Jul 2. J Clin Oncol. 2012. PMID: 22753910 Free PMC article. Clinical Trial.
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, de Castro Faria S, Hart S, Wood J, Jayaraman R, Ethirajulu K, Zhu J. Younes A, et al. Among authors: copeland a. J Clin Oncol. 2012 Nov 20;30(33):4161-7. doi: 10.1200/JCO.2012.42.5223. Epub 2012 Sep 10. J Clin Oncol. 2012. PMID: 22965964 Free PMC article. Clinical Trial.
Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Oki Y, et al. Among authors: copeland a. Clin Cancer Res. 2013 Dec 15;19(24):6882-90. doi: 10.1158/1078-0432.CCR-13-1906. Epub 2013 Oct 4. Clin Cancer Res. 2013. PMID: 24097867 Free PMC article. Clinical Trial.
488 results